CoChat

Treatment of NRAS-Mutant Melanoma

Open access
Johnson, Douglas B., Puzanov, Igor · 2015 · Current Treatment Options in Oncology

The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.

Abstract

NRAS mutations in codons 12, 13, and 61 arise in 15-20 % of all melanomas. These alterations have been associated with aggressive clinical behavior and a poor prognosis. Until recently, there has been a paucity of promising genetically targeted therapy approaches for NRAS-mutant melanoma (and RAS-mutant malignancies in general). MEK inhibitors, particularly binimetinib, have shown activity in this cohort. Based on pre-clinical and early clinical studies, combining MEK inhibitors with agents inhibiting the cell cycling and the PI3K-AKT pathway appears to provide additional benefit. In particular, a strategy of MEK inhibition and CDK4/6 inhibition is likely to be a viable treatment option in the future, and is the most promising genetically targeted treatment strategy for NRAS-mutant melanoma developed to date. In addition, immune-based therapies have shown increasing activity in advanced melanoma and may be particularly effective in those with NRAS mutations. Combination strategies of immune and targeted therapies may also play a role in the future although clinical trials testing these approaches are in early stages.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11864-015-0330-z

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 82 references

Cited by

See all 139

Metadata

Authors
Johnson, D. B., & Puzanov, I.
Affiliations
Vanderbilt-Ingram Cancer Center (US)
Corresponding author
Johnson, Douglas B.
Venue
Current Treatment Options in Oncology
Published
2015-03-22
Volume
16
Issue
4
Pages
15-15
ISSN
  • 1527-2729 (ISSN-L)
  • 1534-6277
OpenAlex
W2051875203
Cited by
139
References
82
Citations by year
2026: 5 · 2025: 10 · 2024: 13 · 2023: 8 · 2022: 13 · 2021: 10 · 2020: 16 · 2019: 11 · 2018: 22 · 2017: 19 · 2016: 9 · 2015: 3
FWCI
1.71
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Current Treatment Options in Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (K12 CA 0906525, K12CA090625)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords
NRAS-mutant melanoma, RAS mutations, MEK inhibitors, binimetinib, CDK4/6 inhibition, PI3K/Akt signaling, combination therapy, immune checkpoint inhibitors, immunotherapy, targeted therapy, advanced melanoma
MeSH terms
Antineoplastic Agents, Humans, Immunotherapy, Melanoma, Membrane Proteins, Mutation, GTP Phosphohydrolases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of NRAS-Mutant Melanoma. https://app.cochat.ai/papers/10.1007/s11864-015-0330-z
The paper
Johnson, D. B., & Puzanov, I. (2015). Treatment of NRAS-Mutant Melanoma. Current Treatment Options in Oncology. https://doi.org/10.1007/s11864-015-0330-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.